The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
|Articles|November 20, 2012
AJMC Live Meeting Slideshow
Check out photos from The American Journal of Managed Care's first annual live meeting, "Translating Evidence-Based Research into Value-Based Decisions in Oncology," which took place on November 16. The meeting was held at the Hyatt Regency Inner Harbor in Baltimore, MD.
Advertisement
Check out photos from The American Journal of Managed Care's first annual live meeting, "Translating Evidence-Based Research into Value-Based Decisions in Oncology," which took place on November 16. The meeting was held at the Hyatt Regency Inner Harbor in Baltimore, MD.
Advertisement
Related to this article
Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.
Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.
At NASP's inSPire2026, covered entities and manufacturers debate 340B program reform, contract pharmacies, and the 2027 rebate model.
Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
Tavapadon for Parkinson Disease Approved by FDA
3
Access and Innovation in North Carolina’s Research Triangle
4
Biomarker-Driven Care Is Racing Ahead of the Systems Built to Support It
5